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Background: A colorectal tumor is not an isolated entity growing in a restricted location of the body. The patient’s
gut environment constitutes the framework where the tumor evolves and this relationship promotes and includes a
complex and tight correlation of the tumor with inflammation, blood vessels formation, nutrition, and gut
microbiome composition. The tumor influence in the environment could both promote an anti-tumor or a
pro-tumor response.
Methods: A set of 98 paired adjacent mucosa and tumor tissues from colorectal cancer (CRC) patients and 50
colon mucosa from healthy donors (246 samples in total) were included in this work. RNA extracted from each
sample was hybridized in Affymetrix chips Human Genome U219. Functional relationships between genes were
inferred by means of systems biology using both transcriptional regulation networks (ARACNe algorithm) and
protein-protein interaction networks (BIANA software).
Results: Here we report a transcriptomic analysis revealing a number of genes activated in adjacent mucosa from
CRC patients, not activated in mucosa from healthy donors. A functional analysis of these genes suggested that this
active reaction of the adjacent mucosa was related to the presence of the tumor. Transcriptional and
protein-interaction networks were used to further elucidate this response of normal gut in front of the tumor,
revealing a crosstalk between proteins secreted by the tumor and receptors activated in the adjacent colon tissue;
and vice versa. Remarkably, Slit family of proteins activated ROBO receptors in tumor whereas tumor-secreted
proteins transduced a cellular signal finally activating AP-1 in adjacent tissue.
Conclusions: The systems-level approach provides new insights into the micro-ecology of colorectal tumorogenesis.
Disrupting this intricate molecular network of cell-cell communication and pro-inflammatory microenvironment could
be a therapeutic target in CRC patients.
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Colorectal cancer (CRC) is a complex disease in which
many genes, proteins, and molecular processes are im-
plicated. Proteins do not work independently in a tumor
cell, but are organized into co-regulated units or path-
ways that perform a common biological function [1].
Relevant molecular mechanisms involved in cancer are
gene regulation, signaling, cell metabolism, and the con-
nections between them, among others [2]. In addition
to the tumor cell intrinsic complexity, increasing data
support the main role of tumor microenvironment in
the mechanisms of CRC progression [3-5]. Tumor mi-
croenvironment is composed by a heterogeneous popula-
tion of stromal cells such as fibroblasts and immune cells,
extracellular matrix components and secreted factors. All
these components work orchestrated by molecular trans-
ducers like integrins engaging cell-cell and cell-matrix sig-
naling that in turn enhance tumor growth [6].
Besides, a colorectal tumor is not an isolated entity
growing in a restricted location of the body. An active
communication exists not only between different cell
communities within the tumor bulk but also between
the tumor and the non-tumor distant mucosa. Hence,
the patient’s gut environment constitutes the framework
where the tumor evolves and this relationship promotes
and includes a complex and tight correlation with in-
flammation, blood vessels formation, nutrition and gut
microbiome composition [7]. Consequently, studying the
micro-ecology context of a tumor is central to under-
stand colorectal carcinogenesis. The tumor influence on
environment could both promote an anti-tumor and a
pro-tumor response. Some microenvironments, particu-
larly those associated with tissue injury, are favorable
for progression of mutant cells, whereas others restrict
it. Cancer cells can also instruct surrounding tissues to
undergo changes that promote malignancy [8].
Field cancerization or the field-effect is a theory first
described by Slaughter et al. in oral carcinoma [9]. In
the initial phase of the multistep carcinogenesis, a stem
cell acquires genetic alterations and forms a “patch”, a
clonal unit of altered daughter cells. Further alterations
convert the “patch” into a field of pre-neoplastic cells.
Although only one cell becomes tumoral, the remaining
field (adjacent mucosa) continues in a “pre-neoplastic-
state” composed of morphologically normal, but biologic-
ally altered epithelial cells. Since this field is a pre-tumor
site predisposed towards development of cancer, this hy-
pothesis could explain local recurrences after surgery [10].
Understanding the complex ways in which cancer cells
interact with their surroundings, both locally in the tumor
organ and systemically in the body as a whole has implica-
tions for effective cancer prevention and therapy. In con-
trast to the gene-centric view, a systems biology approach
(defined as the analysis of the molecular relationshipbetween genes and proteins as a whole) can be useful
to depict a global view of the cancer disease not only as
a tumor cell but as an intricate systemic disease [11].
In this study, mRNA expression from paired tumor (T)
and adjacent mucosa from CRC patients (A) and mRNA
from mucosa healthy donors (H) were measured using
microarrays. The inclusion of samples from healthy sub-
jects has allowed us assessing whether adjacent mucosa
from colon cancer patients differs from healthy donors’
mucosa possibly due to the tumor presence. Indeed, a
number of differentially expressed genes (DEG) were
found between these two entities (A vs. H). Considering
their level of expression in tumor tissues, these DEGs
were classified as “Tumor-like”, “Trend” or “Adjacent-
specific” (A vs. T) patterns. To explain the mechanisms
that regulate these patterns of differential expression,
networks mimicking transcription regulation were used to
search for those transcription factors directly influencing
DEG. Then, a systems biology approach using PPIN was
applied to describe a crosstalk between cytokines and
other proteins secreted by the tumor and receptors acti-
vated in the adjacent colon tissue; and vice versa, pro-
viding new insights into the micro-ecology of colorectal
tumorigenesis. Finally, relevant cytokines and receptors
up-regulated in tumor tissue were identified comparing
T vs. H expression (Figure 1). Further elucidation of
these interactions could be helpful in the development
of novel therapeutic strategies oriented to disrupt this
molecular crosstalk.
Results
Characterization of differentially expressed genes
between adjacent and healthy mucosa
A principal component analysis (PCA) was done to ex-
plore the variability of the transcriptomic data from our
246 samples (Figure 2A). As expected, tumor samples
appeared as an independent cluster (T in red). Surpris-
ingly, adjacent paired mucosa (A in blue) were also
clearly separated from healthy mucosa (H in green),
reflecting a large number of differentially expressed
genes (DEG) between them. A total of 895 genes were
differentially expressed at FDR < 1% and log2 mean differ-
ence > 1 between adjacent and healthy mucosa (Additional
file 1: Table S1). Interestingly, 88% of these genes were
over-expressed in adjacent mucosa (Figure 2B).
The functional enrichment analysis of these genes
identified the classical pathways involved in cancer and
were highlighted by a significant enrichment of func-
tions related to Inhibition of matrix metalloproteinases,
Cell adhesion molecules, cytokine-cytokine receptor in-
teraction, TGF-beta signaling pathway, integrin signal-
ing pathway, complement and coagulation cascades,
wound healing, response to external stimulus, inflam-
matory response and soluble fraction, among others (see
HEALTHY MUCOSA (H)
N = 50
ADJACENT MUCOSA (A)
N = 98
CRC TUMOR (T)
N = 98
PAIRED
Differentially Expressed 
Genes (DEG)
Patterns
of DEG expression
• Tumor-like
• Trend
• Adjacent-specific
Transcriptional 
Regulation 
Analysis
Cross-talk 
network over-expressed genes in CRC-tumor 
(Secreted and Receptors)
DEG
VALIDATION
(public datasets)
Cellular
classification
(public dataset)
over-expressed genes
(Secreted and Receptors)
Figure 1 Work flow chart. The central core of the analysis is the comparison between adjacent mucosa and healthy mucosa at transcriptomic
(gene expression data) and transcriptional (regulatory network) level. Independent public datasets were used to validate the results. In a second step,
tumor tissue was used to search for different DEG patterns. Finally, a crosstalk network was inferred to decipher molecular communication between
the tumor and the adjacent gut underlying DEG. Public data was used to elaborate a cellular classification of genes implicated in the crosstalk.
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Table S3 and Additional file 4: Figure S1). This functional
analysis suggested an active reaction of the adjacent mucosa
related to the presence of the tumor or a more passive reac-
tion induced by factors released from the tumor.
Public transcriptomic data analyzing adjacent and healthy
mucosa were used to validate the list of DEG. As a result,
60% of the genes were validated at FDR 1%. At FDR 5%,
91% of the genes were validated (Additional file 5: Table S4Figure 2 Gene expression differences between adjacent and healthy
the samples based on their gene expression levels. Tumor samples (red), ad
(green) were plotted in 1st and 2nd principal components. B. MA Plot repre
mucosa samples. In red, those probes with a FDR < 1% and log2 mean diffand Additional file 4: Figure S2). These results should be
interpreted with caution because each sample type was ana-
lyzed in different experiments and, though we normalized
the data jointly, we cannot exclude strong batch or la-
boratory effects. We could not find a dataset like ours,
in which healthy and adjacent colon mucosa were ana-
lyzed simultaneously.
Figure 3A shows a hierarchical clustering performed
with the set of DEG between adjacent mucosa (A) andmucosa samples. A. PCA scatter plot representing the dispersion of
jacent mucosa samples (blue) and samples from healthy donors
senting gene expression differences between adjacent and healthy
erence > 1.
Figure 3 (See legend on next page.)
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Figure 3 DEG characterization. A. Hierarchical clustering of 1230 over-expressed and 136 under-expressed probes that correspond to 788 and
107 genes respectively classifying the 246 tissue samples into three clusters of healthy mucosa (green), tumors (red) and adjacent mucosa (blue).
Highlighted in black, the group of 24 adjacent samples showing an extreme phenotype. B. Representative DEG patterns are displayed. DEG
between adjacent and mucosa were classified as “Tumor-like”, “Trend” and “Adjacent-specific” genes. C. PCA using “Adjacent-specific” DEG. Tumor
samples (T) are painted in red, adjacent samples (A) in blue and healthy mucosa (H) in green. The 24 adjacent samples showing an extreme
phenotype are circled with a dot line.
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tissues were perfectly classified, including the tumors
(T) that did not participate in the gene selection. Re-
garding genes, three patterns of expression were identi-
fied as shown in Figure 3B: a) “Tumor-like” (A = T > H
or H > A = T) when genes in A had similar pattern as T
(349 genes); b) “Trend” (T > A > H or H > A > T) when
genes in A had an intermediate expression between H
and T (132 genes); and c) “Adjacent-specific” (A < (T,H)
or A > (T,H)), when genes were specifically de-regulated
in A when compared to either T or H, irrespective of
the relationship between T and H (414 genes). The size
of this latter group was a surprise that lead us to explore
in detail a crosstalk between the tumor and the adjacent
mucosa.
Regarding enriched functions for these gene patterns,
Tumor-like functions included AP-1 transcription factor
network, COX reactions or activation of AP-1, whereas
Adjacent-specific functions were enriched in axon guid-
ance, PPAR signaling pathway or BMP2 signaling pathway,
among others. These results suggest different functions for
each gene expression pattern, though Integrin signaling
pathway, complement cascade, adhesion or Interferon sig-
naling were functions shared by the two patterns (see
complete list in Additional file 6: Table S5).
Adjacent mucosa samples appeared divided into two
groups in the hierarchical clustering analysis (Figure 3A).
The smallest of them, with 24 samples, was characterized
by high expression in most of adjacent-specific genes. A
PCA performed with these adjacent-specific genes showed
that the second component was capturing the specificity
of this sample cluster and that adjacent mucosa were more
similar to tumor than to healthy mucosa (Figure 3C). In
fact, the original PCA analysis with all genes also identified
these adjacent mucosa samples as highly variable in the
second component (Figure 2A).
These clusters were not associated with the clinical pa-
rameters gender, age and tumor progression neither with
technical parameters RNA integrity value (RIN), 260/230
ratio and plate. In addition, a functional analysis includ-
ing differentially expressed genes between these two
clusters did not show specific functions but essentially
those described as characteristic of adjacent mucosa.
These results suggest that the smaller cluster of adja-
cent samples was just an extreme phenotype of these
samples. Interestingly, this pattern was also observed inthe validation dataset (see heatmap in Additional file 4:
Figure S2).
Transcriptional regulation of differentially expressed
genes between adjacent and healthy mucosa
We hypothesized that this differential expression could
be triggered by a transcriptional program, activated only
in adjacent mucosa by the presence of the tumor, and
normally silenced in healthy mucosa. This hypothesis
was supported by the GSEA results, in which 312 tran-
scription factors motifs were found to be statistically
associated with the adjacent mucosa phenotype (nom-
inal p-value < 0.01) but none was found associated to
healthy mucosa phenotype (Additional file 3: Table S3).
To further explore this hypothesis, transcriptional
networks were inferred and compared using gene ex-
pression data of adjacent and healthy mucosa (see
Additional file 4: Figure S3). Venn diagram in Figure 4A
shows the overlap between nodes of each network. The
vast majority of healthy mucosa nodes were also active
in adjacent mucosa network whereas 3120 new nodes
appeared specific to the adjacent mucosa and 668
nodes disappeared from the network. As expected,
DEG between adjacent and healthy mucosa were over-
represented in the new active nodes of the adjacent
mucosa network (empirical p-value < 10−4) suggesting
that DEG are not only performing common functions
but also co-regulated in a sub-transcriptional network
not active in healthy mucosa samples. Out of 895 DEG,
60 (13%) were transcription factors (TF), and random
re-sampling of genes among the complete dataset re-
vealed that DEG were significantly enriched in TF (em-
pirical p-value < 0.001). Among these 60 TF, 35 were
specific of the adjacent mucosa transcriptional network.
TF were ranked taking into account the total number
of their targets (degree) and the proportion of targets
in our DEG list. This rank suggested sub-networks spe-
cifically active in adjacent mucosa tissue. TF with higher
rank were more specific of adjacent mucosa, and showed
higher values of eccentricity (a topological network meas-
ure of the spreading of a node in the network) and lower
values of closeness centrality (Table 1).
Genes from the AP-1 complex (Fosb and Jun) ranked
first in the TF list. The AP-1 subunits Fos, Junb, Mafb
and Atf3 also appeared in the list. Previous GSEA ana-
lysis also had revealed as most significant motive “Genes
AB
C
Figure 4 (See legend on next page.)
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Figure 4 DEG analysis in the framework of transcriptional networks. A. Venn Diagram showing the overlap between nodes in adjacent
mucosa transcriptional network (blue) and healthy mucosa transcriptional network (green). DEG were merged with the two transcriptional
networks. B. Expression correlation between transcription factors Jun and Fos in adjacent (blue) and healthy mucosa (green). C. Gene expression
levels of AP-1 subunits in healthy mucosa (green) adjacent mucosa (blue) and tumor tissue (red).
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start site containing the motif TGACTCANNSKN which
matches annotation for JUN” (p-value = 0.002, and FDR
q-value = 0.015, Additional file 4: Figure S4). A high cor-
relation existed between the expression of Jun and Fos
AP-1 subunits in adjacent mucosa but not in healthy
mucosa (Spearman’s correlation 0.67 and 0.23 respect-
ively; Figure 4B). Interestingly, these TF belonged to the
“tumor-like” genes pattern (Figure 4C). Fos, Jun, Fosb
and Junb did not appear in healthy mucosa transcrip-
tional network highlighting their idiosyncratic role in
adjacent mucosa. The family of transcription factors
NR4A1, NR4A2 and NR4A3 also ranked in top posi-
tions. Other TF such as GLI3, BCN2, EBF1 and ZEB1
were also significant because of their high rank in the
network and large number of DEG targets.
Deciphering a crosstalk between adjacent mucosa and
tumor through a protein-protein interaction network
Changes in adjacent mucosa not detected in healthy mu-
cosa might be a direct response in front of tumor stimulus
based on a physical crosstalk between the cells (Figure 1).
This molecular communication could be through the
direct interaction between secreted proteins and their
corresponding membrane receptors. The following strat-
egy was applied to identify interactions compatible with
this hypothesis: 1) Search for over-expressed genes in tu-
mors compared to healthy mucosa in addition to previous
DEG. 2) Identify those that code for secreted proteins and
membrane receptors. 3) Construct a protein interaction
network with the selected genes. 4) Identify interaction
pairs that reflect cellular communication in both direc-
tions: from tumor to adjacent (efferent pathway) and vice
versa (afferent pathway).
From the 788 over-expressed genes in adjacent mucosa
vs. healthy mucosa, 324 (41%) corresponded to secreted
(n = 111) or membrane (n = 213) genes. In addition, 442
genes (250 secreted and 192 membrane) over-expressed in
tumors were included in the analysis. A level 0 (only direct
interactions) protein-protein interaction network was re-
trieved using the 766 up-regulated secreted/membrane
genes in adjacent and tumor samples as input. The
resulting network included 291 nodes connected by
596 interactions, the majority of them integrated in a
giant component (Figure 5A). A functional analysis of
this network revealed cell adhesion, response to exter-
nal stimulus, response to wounding, and anatomicalstructure development as the most statistically signifi-
cant functions (Additional file 7: Table S6).
A curated analysis of the network revealed 84 crosstalk
interactions (Table 2), 61 of them efferent (tumor se-
creted proteins linked to a receptor in adjacent mucosa
tissue), and 23 afferent (adjacent mucosa secreted pro-
teins linked to a receptor in tumor). Figure 5B shows an
abstraction of the original network restricted to crosstalk
interactions. It is remarkable that 6 out of 23 afferent in-
teractions (26%) included members of the Slit family of
secreted proteins, which emerged as relevant players in
tumor crosstalk determining the adjacent mucosa re-
sponse. In the network, Slit2 and Slit3 were redundantly
activating Robo1, Robo2, Robo4 and ITGA1 receptors in
tumor. Slit family followed an adjacent-specific pattern
of expression (see Figure 6A). Due to its importance,
and as a proof of concept of the overall strategy of gene
selection, inmunohistochemical staining was done to
asses the protein expression of Slit2 and the receptor
Robo2. Slit2 was expressed in adjacent epithelial cells
and also in stromal cancer cells. Robo2 was expressed in
both epithelial and stromal cells in cancer tissue but not
in adjacent tissue (Figure 6B). Other interesting afferent
crosstalk pairs involved LRP8 receptor in tumor acti-
vated by a double stimulus of RELN and CLU proteins
secreted by adjacent mucosa, and VIP, an intestinal pep-
tide that causes vasodilatation, linked to MME receptor
in tumor cells.
Efferent interactions were more numerous and in-
cluded interleukins (IL-8), extracellular-matrix compo-
nents (Fibronectin, Collagen) or molecules related to
invasion like SPARC linked with receptors such as integ-
rins or complement receptors (see Table 2 for specific
pairs). Interestingly, the vascular endothelial growth factor
receptor NRP2, over-expressed in adjacent mucosa, inter-
acted with a plethora of candidate activating secreted fac-
tors from tumors such as VEGFA or SEMA3F. Another
interesting finding was the over-expression of LIF in
tumor, whose receptor LIFR was over-expressed in adja-
cent mucosa but not in the tumor. These results were
highly indicative of an active crosstalk between cells in the
gut microenvironment that triggers an intra-cellular sig-
naling response. The protein-protein interaction network
also revealed autocrine signals within tumor or adjacent
mucosa. For example, the vascular endothelial growth fac-
tor receptor FLT1 was found linked with its ligand
VEGFA, both over-expressed in tumor samples.
Table 1 List of transcription factors differentially expressed between adjacent and healthy mucosa samples
Gene symbol Connections DEG connections Rank P-value Eccentricity Closenness centrality Healthy mucosa network
FOSB 4 4 1.000 <1.00E-04 9 0.209 NO
JUN 2 2 1.000 <1.00E-04 11 0.151 NO
NR4A2 5 5 1.000 <1.00E-04 9 0.204 NO
OSR2 12 12 1.000 <1.00E-04 8 0.234 NO
ZBTB16 1 1 1.000 <1.00E-04 9 0.200 NO
EGR2 10 9 0.900 <1.00E-04 8 0.247 NO
NR4A3 9 8 0.889 <1.00E-04 8 0.249 NO
EBF1 162 143 0.883 <1.00E-04 7 0.294 YES
HEY2 24 21 0.875 <1.00E-04 8 0.266 NO
NR4A1 16 14 0.875 <1.00E-04 8 0.240 NO
PRRX1 30 26 0.867 <1.00E-04 7 0.289 NO
EGR1 13 11 0.846 <1.00E-04 9 0.217 YES
FOS 6 5 0.833 <1.00E-04 10 0.178 NO
JUNB 5 4 0.800 <1.00E-04 10 0.178 NO
MEOX2 75 60 0.800 <1.00E-04 7 0.303 NO
ZFPM2 133 106 0.797 <1.00E-04 7 0.296 NO
ERG 76 60 0.789 <1.00E-04 8 0.287 NO
TSHZ2 109 85 0.780 <1.00E-04 7 0.302 NO
FOXC1 27 21 0.778 <1.00E-04 8 0.268 NO
HLF 84 65 0.774 <1.00E-04 7 0.301 NO
MEIS2 133 100 0.752 <1.00E-04 8 0.305 NO
CREB5 32 24 0.750 <1.00E-04 8 0.278 NO
PRDM6 83 62 0.747 <1.00E-04 7 0.293 NO
GLIS2 79 58 0.734 <1.00E-04 7 0.302 NO
HAND2 138 101 0.732 <1.00E-04 7 0.289 NO
EGR3 11 8 0.727 <1.00E-04 8 0.263 NO
SOX18 40 29 0.725 <1.00E-04 7 0.274 NO
ZNF423 79 57 0.722 <1.00E-04 8 0.303 YES
PHOX2B 60 42 0.700 <1.00E-04 8 0.275 YES
KLF7 133 92 0.692 <1.00E-04 7 0.313 NO
GLI3 217 150 0.691 <1.00E-04 7 0.325 NO
MEIS1 113 77 0.681 <1.00E-04 8 0.301 YES
KLF2 15 10 0.667 <1.00E-04 8 0.261 YES
TSHZ3 80 52 0.650 <1.00E-04 8 0.302 YES
NKX2-3 75 47 0.627 <1.00E-04 8 0.290 NO
BNC2 252 148 0.587 <1.00E-04 7 0.334 NO
PITX2 26 15 0.577 <1.00E-04 9 0.244 YES
PRDM8 70 40 0.571 <1.00E-04 7 0.304 YES
NR2F2 141 78 0.553 <1.00E-04 7 0.334 YES
TSC22D3 29 16 0.552 <1.00E-04 7 0.282 NO
PBX3 186 102 0.548 <1.00E-04 7 0.337 YES
ZEB1 264 139 0.527 <1.00E-04 7 0.343 YES
FOXF1 62 31 0.500 <1.00E-04 7 0.312 YES
ZNF532 110 52 0.473 <1.00E-04 7 0.326 YES
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Table 1 List of transcription factors differentially expressed between adjacent and healthy mucosa samples (Continued)
CAMTA1 68 30 0.441 <1.00E-04 7 0.318 YES
JAZF1 172 74 0.430 <1.00E-04 7 0.334 NO
AFF3 31 11 0.355 <1.00E-04 7 0.295 YES
NFIC 131 43 0.328 <1.00E-04 7 0.339 YES
ZEB2 74 24 0.324 <1.00E-04 7 0.324 YES
TCF4 408 129 0.316 <1.00E-04 6 0.371 YES
BCL6 36 11 0.306 <1.00E-04 7 0.309 NO
NR1H4 77 22 0.286 <1.00E-04 8 0.282 YES
MAFB 125 23 0.184 <1.00E-04 6 0.313 YES
HOXB13 93 14 0.151 <1.00E-04 8 0.264 NO
ATF3 4 3 0.750 0.0003 10 0.184 NO
ZBTB20 149 13 0.087 0.0183982 7 0.356 YES
THRB 12 2 0.167 0.0986901 8 0.259 YES
HOXB6 2 0 0.000 1 8 0.227 YES
IFI16 5 0 0.000 1 7 0.247 YES
NEUROD1 12 0 0.000 1 8 0.236 NO
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active stromal cells. In order to assess which compart-
ment was predominantly expressing the proteins in-
volved in the identified crosstalk interactions, we used
the expression data described by Calon et al. [4] who
analyzed profiles of each cell population sorted from
human CRC. As a result, the vast majority of genes were
over-expressed in the stromal compartment (i.e. collagens,
interleukins) indicating their active role in the remodeling
of the surrounding microenvironment (Additional file 8:
Table S7).
To look for hypothetical relationships explaining the
communication loop between TF and membrane re-
ceptors activated in CRC-adjacent mucosa, a network
using as seed proteins AP-1 and membrane receptors
was retrieved. Only experimentally-determined interac-
tions were used to construct this level 1 PPIN (includ-
ing proteins working as bridges between seed proteins
that add information to the studied system). As a result,
a strong physical interaction between these two cellular
components (the extracellular one and the nuclear one)
was found. Twenty-one membrane receptors (out of
22) interact with each other through linker proteins
to transduce a cellular signal across the extracellular
matrix and membrane, finally activating TF belonging
to the AP-1 complex (Additional file 4: Figure S5). It
is remarkable the close relationship found between
ITGA9, ITGA5, CD36, CD93, TGFBR3 and RECK re-
ceptors. Also, this analysis revealed a direct path from
ROR2 receptor and the AP-1 transcriptional sub-network,
being the ligand WNT5A (up-regulated in tumor tissues)
the activator of this signal.Discussion
There is clear evidence of the relevance of the tumor-
microenvironment crosstalk for carcinogenesis [12-15].
Here we describe altered patterns of expression of the
adjacent mucosa from colon cancer patients that could
be a direct response against the tumor or induced by the
tumor. The analysis of transcriptional profiles and the
regulatory networks derived from them allowed us identi-
fying the pathways involved in tumor-microenvironment
crosstalk.
We can not discard that at least part of the differences
found between adjacent and healthy mucosa were ex-
plained by the existence of a pre-neoplastic field in the
gut. Studies of adjacent mucosa of the head and neck tu-
mors indicate that such fields can expand more than
7 cm in diameter [10]. Nevertheless, a study in CRC by
Jothy S. et al. reported a gradient of carcinoembryonic
antigen (CEA) expression expanding only 5 cm. from
the peritumor area [16]. In our study, adjacent tissue
from patients was dissected from the proximal tumor
resection margin, with a minimum distance of 10 cm.
However, a recent paper by Hawthorn et Mojica sug-
gests that the field effect cancerization could be evident
up to 10 cm. from the tumor [17].
Previous studies usually have compared paired tumor
and adjacent mucosa tissues, which can result in mis-
leading interpretations. We have used a large sample of
healthy mucosa as reference for gene expression com-
parisons and have identified a large number of DEG that
can be grouped into three altered patterns: “tumor-like”,
“trend”, and “adjacent-specific”. Our conclusion is that
adjacent normal mucosa is not so normal. In fact,
Figure 5 Crosstalk pathway. A. Circular layout of protein-protein interaction network representing interactions (lines) between over-expressed
genes in adjacent mucosa (purple) and in tumor (orange). Nodes with a green border symbolize membrane proteins whereas red were used to
represent secreted proteins B. Abstraction of the network in which only crosstalk interactions were drawn, using Cerebral view from Cytoscape.
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Table 2 Afferent and efferent pairs in the crosstalk network
AFFERENT PATHWAYS
SECRETED BY ADJACENT MUCOSA LOCATED IN TUMOR MEMBRANE
Gene symbol Function Gene symbol Function
SLIT2 Cell migration/axon guidance ITGA1 Integrin-mediated cellular signalling and
axon guidance
SLIT2 ROBO2 Cell migration/axon guidance
SLIT2 ROBO1
SLIT3 ROBO2
SLIT3 ROBO1
SLIT2 ROBO4 Cell migration/angiogenesis
FGF7 Growth factor activity FGFR4 Regulation of cell proliferation,
differentiation and migration
PTN Growth factor with mitogenic activity SDC3 Organization of cell shape
TIMP2 Metalloendopeptidase inhibitor activity MMP14 Metalloendopeptidase activit (angiogenesis,
cell proliferation…)
MMP3 Regulation of cell migration MMP14
SPOCK1 Cell adhesion MMP14
ISG15 Interferon-mediated signaling pathway NEDD4 Virus-host interaction
VIP Intestinal peptide that causes vasodilation MME Cellular response to cytokine stimulus
MYOC Anatomical structure morphogenesis CD81 Cell proliferation
RELN Neuron migration LRP8 Cytokine-mediated signalling pathway
CLU Platelet and complement activation LRP8
SERPING1 Innate immunity SELE Inflammatory response
CYR61 Cell adhesion/chemotaxis ITGA1 integrin-mediated signaling pathway
FIGF Angiogenesis ITGA9 Integrin-mediated signaling pathway,
cell adhesion
HBEGF Growth factor activity CD82 Metastasis suppressor gene
CXCL12 Immune response CXCR4 Inflammatory response
CFH Innate immunity IGDCC4 Inmunoglobulin
CFD Innate immunity IGDCC4
EFFERENT PATHWAYS
SECRETED BY TUMOR LOCATED IN ADJACENT MUCOSA MEMBRANE
Gene symbol Function Gene symbol Function
IL8 Inflammatory response DARC Inflammatory response
MIF Inflammatory response CALD1 Cellular component movement
PLA1A Lipid catabolic process CALD1
PF4 Immune response and cytokine-mediated
signaling pathway
LDLR Lipid transport and metabolism
WNT5A In the presence of ROR2, inhibits the canonical
Wnt pathway
ROR2 Wnt receptor signaling pathway
REG3A Inflammatory response SDC2 Wound healing/carbohydrate metabolic
process
SPARC Regulation of cell proliferation SDC2
KAL1 Extracellular matrix structural constituent SDC2
PF4 Immune response and cytokine-mediated signaling
pathway
SDC2
FN1 Extracellular matrix structural constituent involved in
multiple cellular functions
SDC2
FN1 ITGA5 Angiogenesis/cell adhesion/wound healing
FN1 IGDCC4 Inmunoglobulin
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Table 2 Afferent and efferent pairs in the crosstalk network (Continued)
FN1 CD36 Antigen processing and presentation, lipid
storage, cell adhesion
FN1 PECAM1 Cell adhesion, signal transduction
TNC Guidance of migrating neurons CNTN1 Notch signaling pathway, cell adhesion
TNC ITGA5 Angiogenesis/cell adhesion/wound healing
TNC ITGA9 Integrin-mediated signaling pathway,
cell adhesion
COL18A1 Inhibits endothelial cell proliferation and
angiogenesis
ITGA5 Angiogenesis/cell adhesion/wound healing
SFRP2 Wnt receptor signaling pathway ITGA5
SPP1 Cell adhesion, response to vitamin D ITGA5
SPP1 ITGA9 Integrin-mediated signaling pathway,
cell adhesion
AGT Renin-angiotensin system AGTR1 Inflammatory response, Rho protein signal
transduction, Renin-angiotensin system
AGT CTSG Immune response
APOC2 Lipid metabolism IGDCC4 Inmunoglobulin
PPBP Chemotaxis and inmune response IGDCC4
PPBP CTSG Immune response
TAC1 Peptide which excite neurons, and are potent vasodilators TACR2 Response to stress
CXCL5 Chemotaxis and inmune response DARC Inflammatory response
CCL2 Chemotaxis and inflammatory response DARC
C4A Inflammatory response IGDCC4 Inmunoglobulin
IGHG1 Innate inmune response IGDCC4
PCSK9 Cellular response to starvation/cholesterol
metabolic proces
LDLR Lipid transport and metabolism
MMP9 Proteolysis ITGA5 Angiogenesis/cell adhesion/wound healing
MMP9 RECK Blood vessel maturation
VEGFA Growth factor active in angiogenesis NRP2 Angiogenesis
PGF Growth factor active in angiogenesis NRP2
ADAM12 Epidermal growth factor receptor signaling pathway ITGA9 Integrin-mediated signaling pathway,
cell adhesion
COL4A1 Angiogenesis CD93 Macrophage activation, cell-cell adhesion
COL4A1 CD36 Antigen processing and presentation,
lipid storage, cell adhesion
COL1A1 Positive regulation of cell migration/positive regulation
of epithelial to mesenchymal transition
DDR2 Cell adhesion, ossification
COL1A1 ITGA5 Angiogenesis/cell adhesion/wound healing
COL1A1 CD93 Macrophage activation, cell-cell adhesion
COL1A1 CD36 Antigen processing and presentation, lipid
storage, cell adhesion
COL1A2 Transforming growth factor beta receptor signaling
pathway/platelet activation/leukocyte migration
CD93 Macrophage activation, cell-cell adhesion
COL1A2 CD36 Antigen processing and presentation, lipid
storage, cell adhesion
COL3A1 Integrin-mediated signaling pathway/blood vessel
develpment
DDR2 Cell adhesion, ossification
COL6A1 Axon guidance/cell adhesion CD36 Antigen processing and presentation, lipid
storage, cell adhesion
COL6A3 Axon guidance/cell adhesion ITGA5 Angiogenesis/cell adhesion/wound healing
COL4A2 CD93 Macrophage activation, cell-cell adhesion
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Table 2 Afferent and efferent pairs in the crosstalk network (Continued)
Cellular response to transforming growth factor
beta stimulus/axon guidance/angiogenesis
COL4A2 CD36 Antigen processing and presentation, lipid
storage, cell adhesion
LAMA4 Cell adhesion ITGA5 Angiogenesis/cell adhesion/wound healing
CFB Complement activation IGDCC4 Inmunoglobulin
SEMA3F Cell migration NRP2 Angiogenesis
EFNA3 Cell-cell signalling EPHA3 Cell adhesion and migration
C3 Complement activation/Fatty acid metabolism CTSG Immune response
INHBA Cell surface receptor signaling pathway TGFBR3 Negative regulation of transforming growth
factor beta receptor signaling pathway
LIF Growth factor activity LIFR Cell proliferation
FN1 Cell adhesion, cell motility, wound healing FGFR1 Cell proliferation, differentiation and
migration
IGHG1 Complement activation FGFR1
ELN Extracellular matrix organization, cell proliferation FGFR1
C3 Complement activation FGFR1
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may miss good cancer biomarkers candidates, because
many genes are deregulated in adjacent mucosa mim-
icking the tumor expression.
The predominant functions of DEG are mainly related
to response to stimulus, extracellular matrix (ECM)
remodeling, organ morphogenesis, and cell adhesion.
Remodeling of the ECM network though controlled
proteolysis regulates tissue tension, generate pathways
for migration, and release ECM protein fragments to dir-
ect normal developmental processes such as branching
morphogenesis [8]. Collagens are major components of
the ECM of which basement membrane type IV and in-
terstitial matrix type I are the most prevalent. Abnormal
expression, proteolysis and structure of these collagens
influence cellular functions to elicit multiple effects on
tumors, including proliferation, initiation, invasion, me-
tastasis, and therapy response [18]. It has been de-
scribed that integrins that connect various cell types
play a vital role in the survival of a growing tumor mass
by orchestrating signaling pathways activated through
cell-cell and cell-matrix interactions [6]. In our system,
integrins ITGA5 and ITGA9 emerged as active signal
transducers, occupying central positions in the cellular
networks. This result suggests that integrins are not only
vital proteins in tumor cells but also in normal-adjacent
cells. Moreover, our results indicate that proteins im-
plicated in the described crosstalk are predominantly
over-expressed by the tumor stroma. This result un-
derscores the important role of this compartment in
CRC carcinogenesis.
One important finding is that DEG are enriched in
transcription factors. This indicates the existence of a
transcriptional program driving the altered expression
pattern observed in adjacent mucosa. A loop includingmembers of the AP-1 family of transcription factors
emerged as the most significant one in the analysis.
Interestingly, these TF are over-expressed in both ad-
jacent mucosa and tumor tissue. AP-1 members homo
or hetero dimerize to assemble the activator protein 1
(AP-1). AP-1 transcription factor acts synergistically
with SMAD3/SMAD4 component and is implicated in
the regulation of a variety of cellular processes including
proliferation and survival, differentiation, growth, apop-
tosis, cell migration, and inflammation [19,20]. Topo-
logically, these nodes have a low centrality but a high
eccentricity in the transcriptional network. This result
can be a little controversial since it is widely accepted
that the more centered a node is the more important
their functional role in the studied system [21]. How-
ever, a recent publication postulates that nodes with
high eccentricity could be quickly activated by external
factors [22]. This observation could explain the radial
position of AP-1 members Jun, Fos, FosB and JunB into
the transcriptional network as important fast effectors
mediating response against the tumor.
We hypothesized that cytokines and other signaling
proteins secreted by the tumor activate membrane re-
ceptors of adjacent mucosa cells that initiate this tran-
scription factor activity. Tumor-secreted growth factors
act as paracrine agents distorting the normal tissue
homeostasis. In turn, tumors are both maintained or
attacked by signals from the surrounding microenvir-
onment inducing stromal reaction, angiogenesis and
inflammatory responses. To gain insight into the mo-
lecular mechanisms underlying this phenomenon, a
bi-tissue PPIN analysis strategy was performed to ex-
tract patterns of receptor activation in both directions
from adjacent mucosa to tumor and vice-versa. Robo
genes appeared as the most recurrently receptors activated
SLIT2
A
T
ROBO2
a b
c d
A
B
Figure 6 Slit2 and Robo2 expression. A. Microarray gene expression for Slit and Robo family of genes. Tumor samples (T) are colored in red,
adjacent samples (A) in blue and healthy mucosa (H) in green. B. Immunohystochemical staining of Slit2 corresponding to normal epithelial cells
from an adjacent mucosa from a cancer-affected patient (a). However, Slit2 antibody stained basically carcinoma-associated fibroblasts and was
nearly absent in tumor cells (b). For Robo2, the staining clearly shows how this protein is restricted to tumor tissue, and depending on the patient
staining only tumor cells (c) or both tumor cells and carcinoma-associated fibroblasts (d). In staining c, tumor and adjacent tissue are marked as T
and A. Carcinoma-associated fibroblast are marked with an arrow in b and d photographs.
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been implicated in regulating a variety of life activities,
such as axon guidance, neuronal migration, neuronal mor-
phological differentiation, tumor metastasis, angiogenesis
and heart morphogenesis [23]. Several studies have dem-
onstrated dual roles for Slit and Robo in cancer, acting as
both oncogenes and tumor suppressors [24]. This bi-
functionality is also observed in their roles as axon guid-
ance cues in the developing nervous system, where they
both attract and repel neuronal migration [25]. In CRC,
Slit2 up-regulation has been reported as beneficial for the
overall survival of patients [26]. Slit is under-expressed in
patients with metastatic colorectal cancer and their over-
expression in cells resulted in an inhibition of cell migra-
tion through AKT-GSK3β signaling pathway. In our data,
no significant association between Slit2 or Slit3 level of ex-
pression and prognosis was found.
CLU-RELN-LRP8 was other afferent axis to consider
for further analysis. CLU codifies the protein Clusterin
that has been described as both tumor suppressor and
pro-survival factor in colon cancer depending on the
intra- and extracellular microenvironment crosstalk [27].
In fact, it has been reported that Clusterin is a protein
that shares the intracellular information with the micro-
environment and it also experiences a systemic diffusion,
acting as a factor that synergistically interacts with their
surrounding microenvironment [28]. Moreover, it has
been proposed as a diagnostic biomarker in colon cancer
[29]. The other CRC-mucosa-secreted protein activating
LRP8 receptor in tumor is Reelin (RELN), a glycoprotein
that plays an important role in neuronal migration
through the activation of lipoproteins receptors such as
LRP8 [30]. Also, Reelin has been proposed as a pro-
metastatic factor due to their role in cancer cell migra-
tion through TGF-β pathway activation [31].
Efferent pathways were also of interest. LIF is a member
of the IL6 family of cytokines that displays pleiotropic
effects on various cell types and organs [32,33]. In our sys-
tem, its receptor LIFR was expressed in the colonic epi-
thelium. It has been reported that LIF stimulates the
Jak/STAT pathway to produce nitric oxide (NO) [34,35].
Based on this, we hypothesize that, in our model, tumor
LIF activates Jak-STAT pathway in normal epithelial
cells through LIFR receptor leading to NO release and
the subsequent creation of a pro-inflammatory environ-
ment. Moreover, in our model, Angiotensinogen (AGT)
was produced by the tumor and their receptor (AGTR1)
was located in membrane from adjacent tissue. Since
Angiotensinogen is the precursor form of the active
peptide Angiotensin, the pair AGT-AGTR1 makes up
the renin-angiotensin system (RAS), usually associated
with cardiovascular homeostasis but recently associated
with tumor growth [36]. RAS could play a synergistic
effect with LIF inducing NO production, leading toinflammation, macrophage infiltration and tumor-induced
fibrosis. In addition to their pro-inflammatory role, it has
been reported that NO can activate notch-signaling path-
way leading to the induction of tumors [37].
Conceptually, an active sub-network includes differen-
tially expressed and connected proteins in a given pheno-
type. Here we have described a sub-network including
membrane receptors over-expressed in normal adjacent
tissue acting together in cell-adhesion and with functions
on cell surface signal transduction that finally activate the
AP-1 transcription factor. ROR2 has emerged as an im-
portant link in the crossroad between cell surface entering
signal and Fos/Jun transcriptional role as previously de-
scribed [38]. ROR2 is tyrosine-kinase receptor that plays
an important role in developmental morphogenesis [39]
and in our network it was activated by the tumor-secreted
WNT5A, a WNT pathway signaling mediator.
We do not exclude the possibility that genes having a
pivotal role in crosstalk between adjacent and tumor tis-
sue also have a direct relationship with prognosis. In our
data, expression of Fos and Jun were found to be pro-
tective when over-expressed in adjacent but not in
tumor tissue (log-rank p-value = 0.042). Further studies
are needed to experimentally corroborate this hypothesis
and to test the utility of these transcription factors as
prognosis biomarkers. Nevertheless, a complex equilib-
rium between positively pro-survival and pro-apoptotic
signals given by the microenvironment ultimately influ-
ences the tumor growth and their plasticity. This could
be one of the reasons why prognosis signatures that only
take into account tumor but not adjacent tissue expres-
sion fail to accurate predict patients’ outcome [40].
The study has some methodological and technical lim-
itations. Though we obtained adjacent mucosa from the
farthest resection margin and usually required at least
10 cm, it is possible that some of the variability observed
among adjacent mucosa might be related to the distance
to the tumor that we cannot analyze. Also, despite a
careful dissection of tumor blocks before RNA extrac-
tion was done, a normal adjacent tissue infiltration can
exist in some tumor samples. Regarding analytical
methods, the network analysis only considered well-
annotated genes. Some TFs were excluded from the
transcriptional network analysis due to their low vari-
ability in our data. For these reasons, some genes with
a putative role in colon tissue remodeling could have
been missed. In fact, we did not find TGF-β, proposed as
an important microenvironment modifier [4] because its
probeset had very low expression level in our microarray.
Finally, our study only included colon specimens, which
could raise a concern about generalizability of the results.
However, we have previously analyzed that the expression
levels are very similar in colon and rectal tumors [41] and
this has been confirmed in the TCGA study [42].
Sanz-Pamplona et al. Molecular Cancer 2014, 13:46 Page 16 of 19
http://www.molecular-cancer.com/content/13/1/46Conclusions
In conclusion, gene expression in cells comprising normal
adjacent tissue in CRC patients is not so normal and this
could have important implications in colorectal cancer
prognosis and progression. A systems-level approach has
been useful to gain insight into the molecular mechanisms
by which adjacent mucosa activates a transcriptomic pro-
gram in response to cytokines and other signaling proteins
secreted by the tumor. We hypothesize that a crosstalk ex-
ists, not only between different cell communities within
the tumor bulk, but also between colorectal tumor cells
and adjacent mucosa, which reacts against the tumor like
against a wound. Tumor-secreted growth factors act as
paracrine agents distorting the normal tissue homeostasis.
In turn, tumors are both maintained and/or attacked
by signals from the surrounding microenvironment
inducing stromal reaction, angiogenesis and inflammatory
responses. Disrupting this intricate molecular network of
cell-cell communication and signal transduction could be
a therapeutic target in CRC patients.Methods
Patients and samples
A set of 98 paired adjacent normal and tumor tissues
from CRC patients and 50 colon mucosa from healthy
donors (246 samples in total) were included in this work.
Patients were selected to form a homogeneous clinical
group of stage II, microsatellite stable (MSS) colorectal
tumors. All had been treated with radical surgery, had
not received adjuvant therapy and had a minimum fol-
low up of three years. Adjacent normal tissue from pa-
tients was dissected from the proximal tumor resection
margin with a minimum distance of 10 cm. Healthy
donors were invited to participate in this study when
they underwent a colonoscopy indicated for screening
or symptoms with no evidence of lesions in the colon
or rectum (Additional file 9: Table S8). In this paper
we use tumor (T), adjacent mucosa (A) and healthy
mucosa (H) to designate the different tissue origins for
the samples analyzed. All patients were recruited at the
Bellvitge University Hospital (Spain) and the Ethics
Committee approved the protocol. Written informed
consent from patients and healthy donors was required
for inclusion in this study.Differential expression analysis
RNA extracted from each sample was hybridized in
Affymetrix chips Human Genome U219. After a quality
control assessment following Affymetrix standards, data
was normalized using the RMA algorithm [43]. Both
raw and normalized data are available in the NCBI’s
Gene Expression Omnibus (GEO) database [44] through
accession number GSE44076.Prior to the identification of differentially expressed
genes, a filter was applied to remove low variability
probes (n = 15,533), which mostly corresponded to non-
hybridized and saturated measures. The remaining 33,853
probes showed a standard deviation greater than 0.3
and were considered for further analysis. A t-test was
used to identify differences in gene expression between
apparently normal adjacent mucosa from CRC patients
(A) and mucosa from healthy donors (H). A probe was
considered differentially expressed when it was signi-
ficant at 1% FDR (q-value method) and showed an
absolute log2 mean difference higher than 1 (double
expression). The same criteria were applied to identify
differentially expressed genes between tumor (T) and
healthy mucosa (H).
To attempt a validation of the differentially expressed
genes, the same methods were applied to compare sam-
ples of healthy colonic mucosa (n = 13) and adjacent mu-
cosa (n = 24) extracted from public datasets GSE38713
[45] and GSE23878 [46].
Functional analysis
Pathway enrichment analysis was performed using two
methods. First, Sigora R package [47] was used, which
focuses on genes or gene-pairs that are (as a combination)
specific to a single pathway. Sigora contains pre-computed
data for human pathways in the KEGG [48], BIOCARTA
[49], NCI [50], INOH [51] and REACTOME [52] reposi-
tories. Second, the gene set enrichment analysis (GSEA)
algorithm was also applied, which uses the ranking of
differences to identify pathways from a large list of pre-
specified sets [53].
Analysis of transcription factors
Transcriptional networks attempt to translate gene ex-
pression correlations into transcriptional relationships
to reconstruct regulatory loops between transcription
factors and their target genes. Transcriptional regu-
lation networks had been previously inferred using
the ARACNe algorithm [54], which identifies direct
regulatory associations between transcription factors
and targets from mutual information measures of
co-expression. The associations, represented as a tran-
scriptional network, were used to identify and characterize
transcription factors de-regulated in adjacent mucosa
from patients when compared to healthy mucosa.
Deregulated transcription factors were ranked using a
score that took into account both topological parame-
ters of the network and the node expression values.
This score divided the number of deregulated nodes
linked to each transcription factor by the total number
of nodes linked to the transcription factor. To assess
statistical significance, a p-value was calculated by re-
sampling 1000 times random lists of genes. For each
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[55] from Cytoscape [56] was used to extract the to-
pological parameters closeness centrality and eccen-
tricity. Only those genes annotated as transcription
factor based on experimental data were used in this
analysis, whereas those annotated “in silico” were not
considered [57,58].Protein-protein interaction network construction and
analysis
Protein interaction data can be represented as networks
were nodes represent proteins and edges represent physical
interactions between them. BIANA software (Biological In-
teractions and Network Analysis) was used to retrieve such
networks [59]. BIANA builds networks by selecting inter-
acting partners for an initial set of seed proteins (i.e., the
relevant proteins), combining experimentally-determined
data from DIP [60], MIPS [61], HPRD [62], BIND [63] and
the human interactions from two high-throughput experi-
ments [64,65]. The integration of multiple sources of inter-
action data into a single repository allows working with an
extensive set of interactions. For our analysis, only human
and experimentally-determined interactions were taken
into account. Cytoscape software and its plug-ins were used
to analyze and visualize the networks.
Cellular classification of tumor proteins implicated in the
crosstalk
Proteins were classified as “epithelial” or “stromal” on
the basis of their gene level of expression in specific cel-
lular subtypes. For this classification, normalized data
from the public dataset GSE39396 was used, which in-
cluded 24 samples corresponding to different human
CRC cell populations: epithelial, endothelial, fibroblasts
and leukocytes [4].
Immunohistochemistry
Slices of paraffin-embedded tissue (4 μm thick) from 5
pairs of matched samples adjacent-mucosa tumor tissue
were used. For antigen retrieval, the slides were boiled
after deparaffinization in a pressure cooker for 10 minutes
in citrated buffer (8.2 mM tri-sodium citrate and 1.98 mM
citric acid, pH6) for Robo2 detection and in EDTA buffer
(1 mM EDTA, 0.05% Tween-20, pH8) for Slit2 detection.
Endogenous peroxidase was blocked with 3% H2O2 during
20 minutes. After blocking during 30 minutes with 1/5 di-
lution of goat serum, primary antibodies were incubated
overnight at 4°C. Primary antibodies were rabbit poly-
clonal against Slit2 (Abcam, ab111128) and rabbit poly-
clonal against Robo2 (Prestige Antibodies, HPA013371),
diluted both 1:100 in antibody diluent (Dako, Copenhagen,
Denmark). Reaction was visualized using EnVision anti-
rabbit antibody system, and developed using DAB-Plus Kit(Dako). Slides were counterstained with Harry’s modified
haematoxylin. As negative control we used EnVision anti-
rabbit antibody system and displayed no reactivity against
any antigen.
Additional files
Additional file 1: Table S1. List of DEG between adjacent and healthy
mucosa.
Additional file 2: Table S2. Sigora functional analysis results.
Additional file 3: Table S3. GSEA functional analysis results.
Additional file 4: Figure S1. GSEA representative results. Red and blue
bar stands for adjacent and healthy mucosa, respectively. Figure S2.
Venn diagram shows the intersection between DEG in our patients series
and DEG in the validation series, both at FDR 1% and FC >2 (adjacent vs.
healthy mucosa). The heatmap on the right shows how DEG extracted
from our discovery set are able to correctly classify healthy and adjacent
samples in the validation set. Highlighted in black, the group of adjacent
samples showing an extreme phenotype. Figure S3. Transcriptional
regulation networks of adjacent (A) and healthy mucosa (B) tissues.
Figure S4. GSEA term “Genes with promoter regions [−2 kb,2 kb] around
transcription start site containing the motif TGACTCANNSKN which
matches annotation for JUN: jun oncogene”. Red and blue bar stands
for adjacent and healthy mucosa, respectively. Figure S5. Protein-protein
interaction network showing the axis membrane receptors – AP-1
transcription factors, activated in adjacent mucosa. Seed proteins are
colored in green (transcription factors) or brown (membrane receptors), and
highlighted in grey. Inferred interacting proteins are colored in light purple.
Additional file 5: Table S4. Gene expression levels of the 895 DEG
between adjacent and mucosa samples, in independent public datasets
GSE38713 and GSE23878. Only 825 out of 895 genes were found in the
validation serie microarray.
Additional file 6: Table S5. List of significant functions stratified by
pattern.
Additional file 7: Table S6. Crosstalk network functional analysis.
Additional file 8: Table S7. Origin of proteins implicated in the
crosstalk which are secreted by the tumor or located in tumor
membrane.
Additional file 9: Table S8. Baseline characteristics of healthy donors
and CRC patients.
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